Karolinska University Hospital signs Memorandum of Understanding with Major Academic Medical Center in the United States

Karolinska University Hospital has signed a Memorandum of Understanding (MOU) with Brigham and Women’s Hospital, which is located in Boston, Massachusetts to Explore Potential for Scientific, Educational, and Cultural Collaboration.

Through this MOU, Karolinska University Hospital will work closely with Brigham and Women’s Hospital, a teaching affiliate of Harvard Medical School, to explore opportunities to work together through research, education, and innovation activities across all areas of medicine.

Areas of focus may include, for example, clinical data analysis AI, precision medicine, cardiac, cancer, pulmonary, neurosciences, immunology, primary care, and women’s health. Both parties intend to explore the possibility of joint research, clinical and teaching programs that will further enhance the leading-edge capabilities in health care of the KUH and BWH with a particular focus on enhancing a sustainable global health care system.

Brigham and Women’s Hospital is an academic medical center based in Boston, Massachusetts and serves patients from the local area, across the United States and 120 countries around the world. A teaching hospital of Harvard Medical School, Brigham and Women’s Hospital has a legacy of clinical excellence and biomedical research. This MOU marks the official start of a formal exploration of how the two parties may work collaboratively together.

The hospital director Björn Zoëga signed a Memorandum of Understanding (MOU), between the parties. A similar agreement around precision medicine and Network Medicine with the Karolinska Institute already exists.
– Through the collaboration, we hope to work together with the Brigham and Karolinska Institute strengthen Karolinska’s position globally and give our staff new opportunities for clinical research as well as clinical knowledge and experience exchanges. We aim to develop care plans together with other world-leading players, which is beneficial for our patients as well as patients globally, says Björn Zoëga, hospital director at Karolinska University Hospital.

Professor Paolo Parini is the academic coordinator for the (MOU) and Director of Research, Education, Development and Innovation of the Department of National and International at Karolinska University Hospital.
– Collaborations like this can give a dose of extra inspiration and innovation to clinicians and researchers. When several strong players work together, the conditions are best for creating something new and groundbreaking, says Paolo Parini.

Through this agreement, the parties will evaluate opportunities to develop joint training and research initiatives as well as joint financing. Additionally, they will explore short, intermediate, and long-term goals that may be articulated in future agreements.

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version